US equities
|
NVDA
$130.82
▼-10.38%
ANT
$87.69
▼-9.76%
MU
$602.14
▼-12.79%
AMD
$425.80
▼-12.96%
AAPL
$343.33
▼-1.68%
SPCX
$129.19
▼-6.67%
MSFT
$487.87
▼-2.09%
AMZN
$247.81
▼-3.72%
NVDA
$130.82
▼-10.38%
ANT
$87.69
▼-9.76%
MU
$602.14
▼-12.79%
AMD
$425.80
▼-12.96%
AAPL
$343.33
▼-1.68%
SPCX
$129.19
▼-6.67%
MSFT
$487.87
▼-2.09%
AMZN
$247.81
▼-3.72%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
bioAffinity Technologies, Inc. - Warrant
(NQ:
BIAFW
)
0.1505
-0.0013 (-0.86%)
Delayed Quote
Updated: 9:30 AM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about bioAffinity Technologies, Inc. - Warrant
< Previous
1
2
3
4
5
Next >
U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
September 03, 2025
From
bioAffinity Technologies
Via
Business Wire
bioAffinity Technologies Appoints New Members to Board of Directors
August 18, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
August 14, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Reports Second Quarter 2025 Results
August 14, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
August 13, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
August 13, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
July 29, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
July 23, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic
July 22, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic
July 15, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
July 09, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
June 26, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
June 24, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board
June 11, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung
June 03, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
May 28, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
May 20, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Reports First Quarter 2025 Results
May 15, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Closing of $3.25 Million Offering
May 07, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Pricing of $3.25 Million Offering
May 06, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
April 17, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
March 31, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer
March 26, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence
March 19, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer
March 13, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth
March 06, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
February 26, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
February 25, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
January 22, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung
January 13, 2025
From
bioAffinity Technologies, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >